Influence of tirofiban hydrochloride on platelet aggregation rate and C reactive protein levels in patients with acute coronary syndrome

Sun Yueling; Yuan Shuli; Sun Bo; Feng Fubin; Tian Xue

doi:10.3760/cma.j.issn.1673-4777.2014.08.004

Abstract：Objective To observe the influence of tirofiban hydrochloride on platelet aggregation rate and levels of C reactive protein (CRP) in patients with acute coronary syndrome (ACS).Methods The patients with ACS (n =102) were randomly divided into routine group (n =51) and tirofiban group (n =51).The routine group was treated with routine medications with anticoagulation,antiplatelet and regulating lipid; tirofiban group was given tirofiban hydrochloride plus routine medications for 48 hours.The platelet aggregation rate induced by plasma ADP and level of CRP were detected before and after tirofiban administration.The recurrent cardiovascular events were recorded during 30-day follow-up in two groups.Results Before treatment,there was no significant difference in platelet aggregation rate and serum CRP levels in tirofiban group and routine group [(48±10)％ vs (50±12)％,(17.8±2.6)mg/Lvs (18.7 ± 1.7)mg/L,respectively,P＞0.05].The levels of platelet aggregation rate and serum CRP after treatment in tirofiban group and routine group were (12 ± 6) ％,(4.3 ± 2.2) mg/L; (26 ± 13) ％,(9.3 ± 2.6) mg/L,respectively.The amplitude of platelet aggregation rate and serum CRP levels were significantly decreased in tirofiban group than those in routine group(P ＜ 0.01).There were no differences in bleeding adverse reactions and 30-day recurrent cardiovascular events between tirofiban group and routine group[2.0％ (1/51) vs 3.9％ (2/51),3.9％ (2/51) vs 5.9％ (3/51),0 vs 2.0％ (1/51),0 vs 0] (all P ＞ 0.05).Conclusions The administration of tirofiban in patients with ACS can rapidly and effectively inhibit platelet aggregation and decrease CRP level.Tirofiban hydrochloride can also stabilize plaque by inhibiting vascular inflammation.